OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OPRX OptimizeRx Corporation

Trading 07-22 10:27:56 EDT

6.54

-0.12

-1.80%

High6.68	Low6.51	Vol29.33K
Open6.66	D1 Closing6.66	Amplitude2.55%
Mkt Cap122.69M	Tradable Cap94.35M	Total Shares18.76M
T/O193.79K	T/O Rate0.20%	Tradable Shares14.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OPRX","market":"US","secType":"STK","nameCN":"OptimizeRx Corporation","latestPrice":6.54,"timestamp":1784730409556,"preClose":6.66,"halted":0,"volume":29333,"delay":0,"changeRate":-0.018018018018018035,"floatShares":14426800,"shares":18759600,"eps":0.35568,"marketStatus":"Trading","change":-0.12,"latestTime":"07-22 10:27:56 EDT","open":6.66,"high":6.68,"low":6.51,"amount":193794.2049681,"amplitude":0.025526,"askPrice":6.56,"askSize":1,"bidPrice":6.51,"bidSize":300,"shortable":3,"etf":0,"ttmEps":0.35568,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784750400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":6.66,"postHourTrading":{"tag":"盘后","latestPrice":6.66,"preClose":6.66,"latestTime":"19:34 EDT","volume":730,"amount":4858.4742,"timestamp":1784676848560,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.827266,"impliedVol":1.1867,"impliedVolPercentile":0.8127},"requestUrl":"/m/hq/s/OPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2648566911","title":"Optimizerx Publishes Corporate Presentation on Ai-enabled Platform for Pharma-hcp-patient Engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2648566911","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648566911?lang=en_us&edition=fundamental","pubTime":"2026-07-01 02:30","pubTimestamp":1782844248,"startTime":"0","endTime":"0","summary":"OptimizeRx publishes corporate presentation on AI-enabled platform for pharma-HCP-patient engagementOptimizeRx outlined fiscal 2026 guidance for revenue of $95 million-$100 million, adjusted EBITDA of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2YsbLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643121886","title":"OptimizeRx shareholders approve 1 million-share increase to 2021 equity plan reserve","url":"https://stock-news.laohu8.com/highlight/detail?id=2643121886","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643121886?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:12","pubTimestamp":1781295121,"startTime":"0","endTime":"0","summary":"OptimizeRx held its annual shareholder meeting on June 9, 2026.Shareholders adopted an amendment to the 2021 Equity Incentive Plan, increasing the share pool by 1 million to 5,450,000.Investors also voted on an evergreen amendment to the equity plan, an advisory executive pay resolution, director elections, and auditor ratification; outcomes were not disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL1M7VJk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637337911","title":"OptimizeRx publishes corporate presentation on AI-driven healthcare marketing platform DAAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2637337911","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637337911?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:01","pubTimestamp":1779375697,"startTime":"0","endTime":"0","summary":"OptimizeRx outlined fiscal 2026 guidance for revenue of USD 95 million to USD 100 million, adjusted EBITDA of USD 21 million to USD 25 million.Reported Q1 2026 revenue of USD 19.8 million, adjusted EBITDA of USD 3.3 million, GAAP net income of USD -0.5 million.Highlighted a trailing-12-month net revenue retention rate of 110%, down from 114% a year earlier.Disclosed USD 20.2 million of cash and cash equivalents, USD 23.6 million of total debt as of March 31, 2026.Listed shares outstanding of about 18,800,000, market capitalization of about USD 97.2 million, stock price of USD 5.18.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief on May 21, 2026, and i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLc3Zqs9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637381023","title":"OptimizeRx partners with DeepIntent to integrate authenticated EHR network into DSP platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2637381023","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637381023?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:31","pubTimestamp":1779363071,"startTime":"0","endTime":"0","summary":"OptimizeRx entered a partnership with healthcare advertising platform DeepIntent to integrate its authenticated electronic health record network into DeepIntent’s demand-side platform.The tie-up gives life sciences marketers programmatic access to validated EHR advertising inventory inside clinician workflows, aiming to improve targeting and measurement as privacy limits tighten on open-web ads.The integration is expected to be available on DeepIntent in Q3 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLKPLgT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4588","SG9999014039.USD","LU2095319765.USD","BK4167","SG9999014005.SGD","IE00B3QW5Z07.USD","OPRX","BK4112","IE00BKPKM429.USD","SG9999014021.USD","SG9999014013.SGD","NDAQ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635752843","title":"OptimizeRx (OPRX) Q1 Loss Tests Bullish Narrative Around Recently Improved Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2635752843","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635752843?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:45","pubTimestamp":1778712342,"startTime":"0","endTime":"0","summary":"OptimizeRx (NasdaqCM:OPRX) opened 2026 with Q1 revenue of US$19.8 million and a reported loss of US$0.5 million, or EPS of US$0.03, setting a more muted tone after a profitable 2025. The company has seen quarterly revenue move from US$21.9 million in Q1 2025 to US$19.8 million in Q1 2026. EPS shifted from a loss of US$0.12 to a smaller loss of US$0.03 as trailing 12 month EPS reached US$0.37. With margins now positive on a trailing 12 month basis and near break even in the latest quarter, the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-oprx/optimizerx/news/optimizerx-oprx-q1-loss-tests-bullish-narrative-around-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-oprx/optimizerx/news/optimizerx-oprx-q1-loss-tests-bullish-narrative-around-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BLSG","OPRX","BK4112","BLSX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635736993","title":"OptimizeRx price target lowered to $11 from $20 at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2635736993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635736993?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:12","pubTimestamp":1778685144,"startTime":"0","endTime":"0","summary":"Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $20 and keeps a Buy rating on the shares. While “disappointed” with th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-price-target-lowered-to-11-from-20-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-price-target-lowered-to-11-from-20-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635842736","title":"OptimizeRx Is Maintained at Equal-Weight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2635842736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635842736?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:06","pubTimestamp":1778684760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 11:06 ET (15:06 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780032","title":"B. Riley Securities Remains a Buy on OptimizeRx (OPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780032?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:37","pubTimestamp":1778679454,"startTime":"0","endTime":"0","summary":"In a report released today, Anderson Schock from B. Riley Securities maintained a Buy rating on OptimizeRx, with a price target of $10.00. Schock c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/b-riley-securities-remains-a-buy-on-optimizerx-oprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/b-riley-securities-remains-a-buy-on-optimizerx-oprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635578096","title":"B. Riley Adjusts Price Target on OptimizeRx to $10 From $11, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635578096","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635578096?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:25","pubTimestamp":1778678712,"startTime":"0","endTime":"0","summary":"OptimizeRx (OPRX) has an average rating of buy and mean price target of $13.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635275552","title":"Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), ProQR (PRQR) and OptimizeRx (OPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635275552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635275552?lang=en_us&edition=fundamental","pubTime":"2026-05-13 11:30","pubTimestamp":1778643015,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB), ProQR (PRQR) and OptimizeRx (OPRX...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-anaptysbio-anab-proqr-prqr-and-optimizerx-oprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-anaptysbio-anab-proqr-prqr-and-optimizerx-oprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FFTY","BK4139","BK4588","XBI","BK4585","LU0128526141.USD","XLV","HCSG","BK4167","PRQR","ANAB","LABU","OPRX","LU0029874061.USD","BK4137","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226585","title":"OptimizeRx reports Q1 EPS 14c, consensus 0c","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226585","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226585?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:14","pubTimestamp":1778624079,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $18.94M, consensus $18.35M. Stephen Silvestro, OptimizeRx (OPRX) CEO commented, “We delivered a solid start to 2026, exceeding c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-reports-q1-eps-14c-consensus-0c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-reports-q1-eps-14c-consensus-0c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635122581","title":"BRIEF-Optimizerx Corp - Enters Credit Agreement With Fifth Third Bank On May 7, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635122581","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635122581?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:32","pubTimestamp":1778621571,"startTime":"0","endTime":"0","summary":"BRIEF-Optimizerx Corp - Enters Credit Agreement With Fifth Third Bank On May 7, 2026 - SEC FilingMay 12  - OPTIMIZERx Corp OPRX.O:OPTIMIZERX CORP - ENTERS CREDIT AGREEMENT WITH FIFTH THIRD BANK ON MAY 7, 2026 - SEC FILINGOPTIMIZERX CORP - CREDIT AGREEMENT INCLUDES $10 MILLION REVOLVER AND $25 MILLION TERM LOAN - SEC FILINGOPTIMIZERX CORP - CREDIT AGREEMENT INCLUDES UP TO $25 MILLION INCREMENTAL ACCORDION FEATURE - SEC FILINGSource text: [ID:n0001448431-26-000009]Further company coverage: OPRX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635023228","title":"OptimizeRx Corp reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635023228","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635023228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:01","pubTimestamp":1778619697,"startTime":"0","endTime":"0","summary":"OptimizeRx Corp reports results for the quarter ended March 31 - Earnings SummaryOptimizeRx Corp OPRX.OQ reported quarterly adjusted earnings of 14 cents per share for the quarter ended March 31, high","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P36S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761247","title":"OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761247","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635761247?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:12","pubTimestamp":1778616725,"startTime":"0","endTime":"0","summary":"OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 75 percent increase over earnings of $0.08 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52506350/optimizerx-q1-adj-eps-0-14-beats-0-00-estimate-sales-19-844m-beat-18-353m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247440","title":"OptimizeRx Q1 revenue beats analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247440?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:10","pubTimestamp":1778616651,"startTime":"0","endTime":"0","summary":"OptimizeRx Q1 revenue beats analyst estimatesOverviewUS healthcare technology provider's Q1 revenue fell 10% yr/yr but beat analyst expectationsAdjusted EPS and adjusted EBITDA for Q1 beat analyst est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635966247","title":"OptimizeRx Corp - Credit Agreement Includes up to $25 Mln Incremental Accordion Feature - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635966247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635966247?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:08","pubTimestamp":1778616490,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1DM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635203242","title":"BRIEF-OPTIMIZERx Q1 Revenue USD 19.8 Million Vs. IBES Estimate USD 18.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635203242","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635203242?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616106,"startTime":"0","endTime":"0","summary":"BRIEF-OPTIMIZERx Q1 Revenue USD 19.8 Million Vs. IBES Estimate USD 18.4 Million\n\n\nMay 12 (Reuters) - OPTIMIZERx Q1 adjusted net income USD 2.7 million vs. IBES estimate USD -31.2 thousand.\n\nQ1 adjusted EBITDA USD 3.3 million vs. IBES estimate USD -193 thousand","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXAA2CB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635202242","title":"OptimizeRx Q1 net loss narrows to $(0.5) million; revenue falls 10% to $19.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635202242","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635202242?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616103,"startTime":"0","endTime":"0","summary":"OptimizeRx posted Q1 revenue of USD 19.8 million, down 10%, while net loss narrowed to USD 0.5 million, or USD 0.03 per share.Adjusted EBITDA rose to USD 3.3 million from USD 1.5 million.Cash and cash equivalents totaled USD 20.2 million at March 31; debt ended quarter at USD 23.6 million after USD 2.7 million of principal repayments.Subsequent to quarter-end, OptimizeRx refinanced with a USD 35 million facility, expecting about USD 1.5 million in annual interest expense savings.Company cut 2026 revenue outlook to USD 95 million-USD 100 million, citing near-term disruption from MFN pricing dynamics and macro factors; adjusted EBITDA view held at USD 21 million-USD 25 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL5BPXj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","NDAQ","LU2095319765.USD","SG9999014013.SGD","BK4167","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","OPRX","BK4585","BK4112","SG9999014039.USD","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242712","title":"OptimizeRx Outlook FY Revenue USD 95-100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242712?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXAA2CB6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242213","title":"OptimizeRx Q1 Adjusted Net Income USD 2.7 Million VS. Ibes Estimate USD -31.2 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242213?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXAA2CB6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.optimizerx.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.3373},{"period":"3month","weight":-0.0206},{"period":"6month","weight":-0.4431},{"period":"1year","weight":-0.4829},{"period":"ytd","weight":-0.4568}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.043426},{"month":2,"riseRate":0.5,"avgChangeRate":-0.003414},{"month":3,"riseRate":0.25,"avgChangeRate":-0.024049},{"month":4,"riseRate":0.5,"avgChangeRate":-0.049925},{"month":5,"riseRate":0.5,"avgChangeRate":0.094804},{"month":6,"riseRate":0.875,"avgChangeRate":0.073964},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.011438},{"month":8,"riseRate":0.625,"avgChangeRate":0.055887},{"month":9,"riseRate":0.5,"avgChangeRate":0.066303},{"month":10,"riseRate":0.375,"avgChangeRate":-0.045261},{"month":11,"riseRate":0.5,"avgChangeRate":0.019799},{"month":12,"riseRate":0.25,"avgChangeRate":-0.029069}],"exchange":"NASDAQ","name":"OptimizeRx Corporation","nameEN":"OptimizeRx Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OptimizeRx Corporation,OPRX,OptimizeRx Corporation股票,OptimizeRx Corporation股票老虎,OptimizeRx Corporation股票老虎国际,OptimizeRx Corporation行情,OptimizeRx Corporation股票行情,OptimizeRx Corporation股价,OptimizeRx Corporation股市,OptimizeRx Corporation股票价格,OptimizeRx Corporation股票交易,OptimizeRx Corporation股票购买,OptimizeRx Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}